Phanes Therapeutics, Inc. Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Phanes Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego that focuses on discovering and developing oncology drugs. It maintains a pipeline in cancer therapy with three Phase 2 trials ongoing for spevatamig, peluntamig, and mavrostobart. The company leverages its proprietary platforms to create novel biologics addressing high unmet medical needs in cancer.

Its lead asset, spevatamig, is a native IgG-like bispecific antibody targeting claudin 18.2 and CD47 and has received FDA orphan drug designation for pancreatic cancer and Fast Track designation for metastatic claudin 18.2-positive pancreatic adenocarcinoma. Phanes is conducting Phase 2 studies in multiple indications, including first-line pancreatic ductal adenocarcinoma in combination with chemotherapy, with about 180 patients dosed globally as of April 2026. In 2026, the company disclosed updated Phase 2 results for spevatamig to be presented at ASCO and AACR.

Get verified Phanes Therapeutics, Inc. emails free

Company overview Employee directory